Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2025 07:30 ET | Source: Attovia Therapeutics, Inc.

Attovia Therapeutics Announces $90 Million Series C Financing to Advance ATTOBODY-based Programs through Clinical Proof of Concept

Series C round led by Deep Track Capital with participation from additional new and existing investors Financing will fund early-to-mid-stage clinical studies for ATTO-1310 in chronic pruritus and...
April 08, 2025 09:00 ET | Source: Codex Labs Corporation

Codex Labs OTC Bia Eczema Relief Lotion Is Awarded Seal of Acceptance from National Eczema Association and Microbiome-Friendly Certification from MyMicrobiome

San Jose, CA, USA, April 08, 2025 (GLOBE NEWSWIRE) -- Codex Labs, a Silicon Valley skintech company, announced that its over-the-counter (OTC) Bia Eczema Relief Lotion has been awarded the Seal of...
March 20, 2025 07:00 ET | Source: Sitryx Therapeutics

Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219

Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease...
March 07, 2025 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

Arcutis today announced new data from two posters shared at the 2025 American Academy of Dermatology Annual Meeting (AAD).
February 28, 2025 09:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

Arcutis today announced that it will present two posters at the 2025 AAD annual meeting which will take place in Orlando, FL, from March 7-11, 2025.
February 26, 2025 10:00 ET | Source: Derm-Biome Pharmaceuticals, Inc

Derm-Biome’s DB-007-5 is highly effective at treating atopic dermatitis and reducing itch in preclinical study, outperforming the current leading topical AD drug

VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company focused on skin health and healthy ageing, is pleased to...
February 26, 2025 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of October 13, 2025
February 24, 2025 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology

Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old
January 29, 2025 11:05 ET | Source: Research and Markets

Dermatology Excimer Laser Market Research and Forecasts 2023-2024 & 2024-2034: Growing Trend Toward Specialized Centers Focused on Advanced Dermatological Treatments

Dublin, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The "Dermatology Excimer Laser Market by Product, by Application, by End-User, and By Region" report has been added to ResearchAndMarkets.com's...
December 16, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Arcutis today announced the submission of an sNDA to the FDA for ZORYVE (roflumilast) cream 0.05% for children aged 2 to 5 for mild to moderate AD.

Next Page keyboard_arrow_right